N. Colombo explains the findings presented at ECC 2015 from the ROSiA study of extended duration of front-line bevacizumab-based therapy; analysis from the AURELIA trial on sensitivity of CT vs CA125 in detecting disease progression; and risk of disease relapse in ovary in case of fertility preserving surgery in ovarian cancer patients.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Janssen Lilly Oncology

Main Sponsors

Amgen Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo Genomic Health Inc. Roche